The transaction, finalized following regulatory clearance, includes two FDA-approved rare tumor therapies: Ogsiveo for ...

Merck KGaA has concluded the previously announced acquisition of SpringWorks Therapeutics for an enterprise value of €3bn ($3.4bn), after receiving regulatory approvals and fulfilling customary ...

Patients with rare diseases are increasingly working to find and fund their own cures. But should they have to?

German pharmaceutical giant Merck has completed a €3 billion ($3. 5 billion) takeover of US biopharmaceutical company ...

A little over two months after it was announced, Germany-based life sciences firm Merck KGaA said Tuesday that it has ...

SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) reported $61.5 million in net product revenue for fiscal Q4 2024 and $172.0 million for the entire year in its preliminary results.

Explore SpringWorks Therapeutics stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for SWTX.

Merck KGaA, Darmstadt, Germany has closed the acquisition of SpringWorks Therapeutics Inc. for an enterprise value of $3.4 billion.

SpringWorks Therapeutics expects the EMA to rule on nirogacestat's marketing authorization for desmoid tumors in Q2 2025. Quiver AI Summary. SpringWorks Therapeutics, Inc. announced that it ...

After months of discussion, Germany’s Merck KGaA said Monday it would buy SpringWorks Therapeutics for $47 a share in cash, a deal with an equity value of nearly $4 billion.

Get the latest news on SpringWorks Therapeutics stock with updates on market trends, financials, and analysis from Benzinga. Stay informed on SWTX performance ...